Product image of Megalotect (Human Cytomegalovirus Immunoglobulin) supplied by GNH India

Megalotect

Active Ingredient:
Human Cytomegalovirus Immunoglobulin
Origin:
EU

Megalotect (Human Cytomegalovirus Immunoglobulin)

Human Cytomegalovirus Immunoglobulin, the active ingredient in Megalotect, is an immunoglobulin presented as a sterile liquid preparation for intravenous use. It provides passive immunity by supplying antibodies that neutralize human cytomegalovirus in patients at risk of severe infection.
GNH India supplies Megalotect as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals, transplant centres and pharmacies worldwide.

Manufacturer / TM Owner

Biotest Pharma Gmbh

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Megalotect is used in the management of cytomegalovirus (CMV) disease and its prevention in immunocompromised patients.

  • Solid organ transplant recipients: reduces the incidence of CMV disease after transplantation.
  • Hematopoietic stem cell transplant recipients: provides prophylaxis against CMV reactivation.
  • Patients with primary CMV infection: aids in viral clearance when conventional antivirals are insufficient.

How It Works

  • Human Cytomegalovirus Immunoglobulin supplies exogenous anti‑CMV antibodies that bind to viral particles, neutralizing their ability to infect host cells and facilitating clearance by the reticuloendothelial system, thereby providing passive immunity to patients with weakened immune defenses.

Side Effects

Megalotect may be associated with infusion‑related and immunologic reactions.

Common Side Effects

  • Fever: transient rise in body temperature during or after infusion.
  • Chills: shaking sensations commonly reported with intravenous immunoglobulins.
  • Headache: mild to moderate headache occurring shortly after administration.
  • Nausea: occasional upset stomach or feeling of queasiness.
  • Rash: mild erythematous skin eruption at the infusion site.
  • Mild hypertension: temporary increase in blood pressure during infusion.

Serious or Rare Side Effects

  • Anaphylaxis: severe allergic reaction requiring immediate medical intervention.
  • Renal dysfunction: acute kidney injury, especially in patients with pre‑existing renal disease.
  • Thromboembolic events: clot formation leading to deep‑vein thrombosis or pulmonary embolism.
  • Hemolysis: destruction of red blood cells causing anemia.
  • Severe hypotension: marked drop in blood pressure during infusion.
  • Aseptic meningitis: rare inflammatory response of the meninges without infection.

Precautions & Warnings

Megalotect should be administered with careful monitoring of patient status and laboratory parameters.

  • Renal impairment: monitor serum creatinine and adjust infusion rate as needed.
  • Thromboembolic risk: assess history of clotting disorders before use.
  • Known hypersensitivity to blood products: avoid administration in allergic individuals.
  • Pregnancy: consider only if potential benefit outweighs potential risk to the fetus.
  • Immunocompromised patients: observe closely for secondary infections.
  • Store at 2-8°C: keep refrigerated, protect from light, do not freeze or shake.

Avoid Interactions

Megalotect may interact with other agents that affect immune function or blood viscosity.

Major Interactions (Avoid)

  • Live vaccines: concurrent use may result in uncontrolled infection.
  • Other CMV hyperimmune globulins: duplication can increase risk of hyperviscosity.
  • High‑dose immunoglobulin therapy: may exacerbate renal and thrombotic complications.

Moderate Interactions (Monitor Closely)

  • Anticoagulants: potential enhancement of bleeding tendency.
  • Nephrotoxic drugs: increased risk of renal injury; monitor renal function.
  • Corticosteroids: may alter immunologic response to the product.

Frequently Asked Questions

Megalotect is a human cytomegalovirus immunoglobulin administered intravenously to provide passive immunity against CMV infection. It is primarily used for prophylaxis and treatment of CMV disease in solid organ and hematopoietic stem cell transplant recipients, as well as in patients with primary CMV infection who require additional antibody support.

The immunoglobulin contains high‑titer antibodies that specifically bind to cytomegalovirus particles. By neutralizing the virus, it prevents cellular entry and replication, and it promotes clearance through opsonization and phagocytosis, thereby reducing viral load and mitigating disease severity in immunocompromised individuals.

The dosing regimen for Megalotect is individualized by the prescribing clinician based on the patient’s weight, transplant type, CMV serostatus, and clinical condition. The prescriber determines the appropriate dose, infusion rate, and treatment duration in accordance with local guidelines and product labeling.

Safety data for Megalotect in pregnancy and lactation are limited. It should be used only if the potential benefit to the mother outweighs any possible risk to the fetus or infant. Clinicians should discuss the risk‑benefit profile with the patient and consider alternative therapies when appropriate.

To order Megalotect, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies, and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details (including cold‑chain logistics), and necessary import documentation.

Megalotect provides passive immunity through antibodies, whereas antiviral drugs such as ganciclovir act by inhibiting viral DNA synthesis. Immunoglobulin therapy can be used in combination with antivirals for synergistic effect, especially in high‑risk transplant patients, but it does not replace antiviral medication when active viral replication is present.

Megalotect must be stored at 2‑8 °C in a refrigerator, protected from light. The product should never be frozen or shaken. Before administration, inspect the vial for particulate matter or discoloration and allow it to reach room temperature if required by the infusion protocol.

Megalotect is given by intravenous infusion under the supervision of qualified healthcare personnel. The infusion rate is typically started slowly and may be increased as tolerated. Vital signs should be monitored before, during, and after the infusion to detect any adverse reactions promptly.

Serious risks include anaphylactic reactions, acute renal dysfunction, thromboembolic events, hemolysis, severe hypotension, and aseptic meningitis. Patients should be observed closely during infusion, and any signs of these complications require immediate medical intervention and possible discontinuation of therapy.

Megalotect is contraindicated in individuals with a known hypersensitivity to human immunoglobulins or any component of the formulation. It should also be avoided in patients with uncontrolled hyperviscosity syndromes or active severe renal impairment unless the benefits clearly outweigh the risks.

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Human Cytomegalovirus Immunoglobulin

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT